EE691 Economic Evaluation and Budget Impact of RVd as Induction Regimen Prior to ASCT in Patients with Newly Diagnosed Multiple Myeloma from the Perspective of the Public Health Sector in Mexico

Compare the costs effectiveness of RVd (lenalidomide, bortezomib and dexamethasone) and D-VTd (daratumumab, bortezomib, thalidomide and dexamethasone) as induction regimen prior to autologous stem cell transplantation (ASCT) and estimate the budget impact associated with the use of RVd in this indication, from the perspective of the public health sector in Mexico.
Source: Value in Health - Category: International Medicine & Public Health Authors: Source Type: research